STALEY CAPITAL ADVISERS’s iShares Biotechnology ETF IBB Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-33,750	Closed	-$4.15M	–	131
2015 Q2	$4.15M	Buy	33,750 +16,500	+96%	+$1.98M	0.46%	47
2015 Q1	$1.98M	Buy	+17,250	New	+$1.9M	0.23%	56

Other funds holding IBB

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

STALEY CAPITAL ADVISERS's IBB Position: Q3 2015 in Review

STALEY CAPITAL ADVISERS sold out of iShares Biotechnology ETF (IBB) in Q3 2015, closing a stake of 33,750 shares — an estimated $4.15M sold.

STALEY CAPITAL ADVISERS first reported a position in IBB in Q1 2015 and held it in 2 quarters. The position peaked at $4.15M in Q2 2015. 415 funds tracked by Wall St. Rank hold IBB as of Q3 2015.

STALEY CAPITAL ADVISERS reported no remaining iShares Biotechnology ETF position as of Q3 2015 after selling out during the quarter.
STALEY CAPITAL ADVISERS sold 33,750 iShares Biotechnology ETF shares in Q3 2015, an estimated $4.15M.
STALEY CAPITAL ADVISERS first reported a position in iShares Biotechnology ETF in Q1 2015 and held it in 2 quarters.
STALEY CAPITAL ADVISERS's iShares Biotechnology ETF position peaked at $4.15M in Q2 2015.
415 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2015.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2015, filed 5 Nov 2015.